Author + information
- Rasmus Rørth,
- Emil Fosbøl,
- Ulrik Madvig Mogensen,
- Kristian Kragholm,
- Gunnar Gislason,
- Christian Torp-Pedersen,
- Lars Køber and
- Søren Lund Kristensen
Background: The ability to work is an important measure of functional capacity and quality of life. We investigated the association between evidence-based medicine (EBM) for treatment of heart failure (HF) and workforce attachment.
Methods: In a nationwide cohort of patients in the workforce prior to first hospitalization for HF and alive 30 days after discharge, we investigated the relation between treatment with EBM and return to work at one-year follow-up by use of logistic regression. Long term risk of workforce dropout or death was assessed by use of Cox-regression, stratified by whether or not optimal dosages of EBM were achieved. All analyses were adjusted for age, sex and comorbidity.
Results: 11677 patients were alive 30 days after discharge. Within these 30 days 6198(53%) began treatment with EBM. At 1-year 8040(69%) had returned to work, with the highest likelihood among patients treated with EBM (OR 1.29 [1.14-1.46]). During an additional 3 years of follow-up patients in EBM had significant reduced risk of workforce detachment or death (Figure1; optimal β-blockers + Renin angiotensin system inhibitors (RASi) HR 0.81 [0.75-0.88], suboptimal β-blockers +RASi HR 0.81 [0.76-0.86], RASi HR 0.86 [0.80-0.92], β-blockers HR 0.88 [0.81-0.96]).
Conclusions: Initiation of EBM following first hospitalization for HF is associated with increased likelihood of return to work. Combination therapy at one-year follow-up is associated with reduced risk of workforce detachment and death.
Poster Hall, Hall C
Sunday, March 19, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1293-249
- 2017 American College of Cardiology Foundation